[Comparison of Cisplatin Plus Etoposide and Carboplatin Plus Etoposide in Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer-A Single-Institution Retrospective Study].

BACKGROUND:The Japanese Guidelines for Diagnosis and Treatment of Lung Cancer recommend concurrent chemoradiotherapy (CRT) with cisplatin plus etoposide (PE) for limited-stage small cell lung cancer (LS-SCLC). When cisplatin administration is difficult, carboplatin plus etoposide (CE) with either sequential or concurrent thoracic radiotherapy is selected. While overseas studies have shown no significant difference in overall survival between PE and CE, evidence in Japan remains limited. METHODS:We retrospectively compared progression-free survival (PFS) between patients treated with PE and those treated with CE among LS-SCLC cases that received CRT between March 2005 and March 2025. RESULTS:A total of 43 patients were included (PE: 24, CE: 19). Most CE patients (89.5%) received CBDCA (AUC5) plus ETP (80 mg/m2). The median PFS was 13.5 months for PE (95%CI: 10.0-NA) and 9.9 months for CE (95%CI: 6.8-NA) (p = 0.369). The adjusted hazard ratio for PE versus CE was 0.85 (95% CI: 0.37-1.97; p = 0.702). The incidence of grade ≥3 neutropenia was 95.8% in PE and 89.5% in CE (p = 0.575), whereas febrile neutropenia occurred in 50.0% and 15.8% of patients, respectively (p = 0.026). CONCLUSION:In this retrospective study of patients with LS-SCLC treated with CRT, no clear differences in PFS or OS were observed between the PE and CE regimens.